PneumoWave has closed a £7.5m Series A funding round, which should enable clinical validation and regulatory submission of its biosensor technology platform for remote wireless diagnosing and monitoring respiratory changes in high-risk patients.
The round comprises £5.2m equity from new investor Scottish National Investment Bank, alongside £2.3m from existing investors Scottish Enterprise, IIG, Equity Gap, Alba Equity and London and Scottish Investment Partners.
Boston-based life science investor Mark Bamforth of Thairm Bio also joined the round as PneumoWave prepares to ramp up its US operations.